Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

November 8th 2016

Humana's Roy A. Beveridge, MD, to Give Keynote at Patient-Centered Oncology Care

With value-based reimbursement now far from its infancy, the chief medical officer for Humana will forecast what’s ahead in payment reform-and how oncology connects with what is happening in primary care, hospitals, and the pharmaceutical industry. Roy A. Beveridge, MD, will open Patient-Centered Oncology Care, which will meet November 17-18, 2016, in Baltimore, Maryland.

November 7th 2016

Meta-Analysis Confirms Clinical Advantage of BRAF/MEK and PD-1 Inhibitors in Melanoma

Surabhi Dangi-Garimella, PhD

Based on a retrospective meta-analysis of clinical trial data, authors of a recent paper in JAMA Oncology concluded that BRAF/MEK and programmed death receptor-1 (PD-1) inhibitors were the most effective treatments that were relatively safe in melanoma.

November 7th 2016

Value of Second Opinion in Prostate Cancer Uncertain, Says Hopkins Study

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Johns Hopkins University has found that second opinions did not change treatment choice among men diagnosed with low-risk prostate cancer.

November 4th 2016

A Diagnostic Tool for Cachexia in Cancer Patients Could Save Lives

Surabhi Dangi-Garimella, PhD

Researchers from Canada’s McGill University have developed a potential tool that can detect early signs of cachexia in cancer patients, which could impact survival.

November 4th 2016

Genetic Counseling Prerequisite Reduced Appropriate Testing, Study Finds

Surabhi Dangi-Garimella, PhD

A new study in the Journal of Oncology Practice has found that the health plan requirement of counseling by certified geneticists could have led to patient access issues in oncology.

November 3rd 2016

ASCO's Collaboration Will Expand the Reach of COME HOME for Oncology Patients

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology (ASCO) has announced that it is collaborating with Innovative Oncology Business Solutions, Inc, on ASCO COME HOME.

Segment 8 - Covering the Gaps in Cancer Survivor Care

November 3rd 2016

Segment 8 - Covering the Gaps in Cancer Survivor Care

How can care providers ensure cancer survivors continue to receive adequate follow-up care post treatment?

Segment 7 - Successful Discussions on Advance Care Planning and EOL

November 3rd 2016

Segment 7 - Successful Discussions on Advance Care Planning and EOL

How can discussions on advance care planning and end-of-life care be successfully broached with patients and their family members?

Segment 6 - Reimbursing Value-Based Oncology Care

November 3rd 2016

Segment 6 - Reimbursing Value-Based Oncology Care

Panelists discussed how patient-centered care can be valuated in the changing healthcare climate.

Segment 5 - An Ideal Patient Portal

November 3rd 2016

Segment 5 - An Ideal Patient Portal

Is there anything like an ideal patient portal that can cater to a broad range of patients? According to Rebekkah Schear, MIA, what patient portals lack is a holistic approach toward the patient.

Segment 4 - Overcoming Barriers With Data Exchange

November 3rd 2016

Segment 4 - Overcoming Barriers With Data Exchange

How can we create more standardized health information platforms that can easily exchange patient information?

Segment 3 - Challenges With Oncology Care Navigation

November 3rd 2016

Segment 3 - Challenges With Oncology Care Navigation

Cancer is a complex disease to treat an patients can be overwhelmed by the number of care providers that they have to consult with. In this scenario, care navigators can provide significant support to patients and their family members.

Segment 2 - Documenting the Treatment Plan

November 3rd 2016

Segment 2 - Documenting the Treatment Plan

Panelists discuss the need for documenting a treatment plan early in patient care.

Segment 1 - Patient-Centered Care and Shared Decisions in Oncology

November 3rd 2016

Segment 1 - Patient-Centered Care and Shared Decisions in Oncology

Joseph Alvarnas, MD, editor-in-chief of Evidence-Based-OncologyTM spoke with Rebekkah Schear, MIA, and Michael Kolodziej, MD, to discuss the progress and challenges in oncology care.

Dr Andrew L. Pecora Outlines Issues Oncologists Have With Value Frameworks

November 2nd 2016

Dr Andrew L. Pecora Outlines Issues Oncologists Have With Value Frameworks

Oncologists are aware of the various value frameworks that have popped up recently, but they are still in the first phase and many oncologists have issues with the frameworks, said Andrew L. Pecora, MD, FACP, CPE, chief innovation officer professor and vice president of cancer services at the John Theurer Cancer Center.

November 1st 2016

Chemo Brain May Have a Solution: Insight

Surabhi Dangi-Garimella, PhD

A new study suggests that a Web-based intervention could improve a cancer survivor’s cognitive function post treatment.

November 1st 2016

CVS Reverses Decision on Physician Dispensing of Oncology Drugs

Surabhi Dangi-Garimella, PhD

CVS Health has reversed its decision on physician dispensing of specialty drugs, originally meant to be implemented by January 1, 2017.

October 31st 2016

Phase I Study Indicates Pembrolizumab an Option in Heavily Pretreated Hodgkin Lymphoma

A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.

October 31st 2016

Researchers Aren't Taking Advantage of Clinical Trial Data-Sharing Project

Surabhi Dangi-Garimella, PhD

A perspective piece, published by researchers from Rutgers University, laments the lack of interest shown by researchers in a clinical trial data-sharing project launched in January 2014.

October 28th 2016

Study Results Could Help Strengthen Response to Checkpoint Inhibitors

Surabhi Dangi-Garimella, PhD

An animal study conducted at the Perelman School of Medicine, University of Pennsylvania, has identified a mechanism to strengthen the immune response of T cells in cancer patients who are treated with checkpoint inhibitors.

This Week in Managed Care: October 28, 2016

October 28th 2016

This Week in Managed Care: October 28, 2016

This week, the top stories in managed care included an announcement that premiums on Obamacare plans are set to increase by 25% on average, a discussion of Medicare Advantage growth at America's Health Insurance Plans' National Conference on Medicare, and recommendations for success with the Oncology Care Model.

Dr Scott Gottlieb: PCOC Is a Good Place to Meet Thought Leaders in Oncology

October 28th 2016

Dr Scott Gottlieb: PCOC Is a Good Place to Meet Thought Leaders in Oncology

Patient-Centered Oncology Care offers attendees the opportunity to meet and interact with high-level people from various segments of the healthcare industry, explained Scott Gottlieb, MD, resident fellow at the American Enterprise Institute.

October 27th 2016

Age Is Not a Risk Factor for Post-Mastectomy Reconstructive Surgery

Surabhi Dangi-Garimella, PhD

Long-term follow-up of women who underwent mastectomy and breast reconstruction subsequent to a breast cancer diagnosis found that the success of the procedure and associated complications were not influenced by the woman’s age.

October 26th 2016

Will a Payer—Provider Collaboration Guarantee OCM Success?

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, oncologists and payers came together to discuss the role of collaboration and data sharing for the successful implementation of the Oncology Care Model.

October 26th 2016

Employers Express Their Concerns With Cancer Care at the COA Summit

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), 2 employer groups and a provider participated on a panel to provide practical insight into the extraordinary challenges and decisions faced by employers and employees with a cancer diagnosis.

Dr Karen van Caulil on Value-Based Oncology Care Models for Large Employers

October 26th 2016

Dr Karen van Caulil on Value-Based Oncology Care Models for Large Employers

When transitioning towards value-based oncology, large employers should look to value-based models that have worked for other conditions, said Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition. These successful payment models include patient-centered medical homes, bundled payments, and accountable care organizations.

Barry Russo Discusses Challenges of Juggling OCM and MIPS

October 26th 2016

Barry Russo Discusses Challenges of Juggling OCM and MIPS

Many oncology practices are still trying to understand the new Oncology Care Model (OCM) structure and focus on data reporting as they simultaneously prepare to adapt to the Merit-based Incentive Payment System (MIPS), said Barry Russo, CEO of The Center for Cancer & Blood Disorders.

October 25th 2016

Pembrolizumab Is FDA-Approved as First-Line for PD-L1—Positive NSCLC

Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda).

October 25th 2016

Strategies for OCM Implementation at the COA Payer Summit

Surabhi Dangi-Garimella, PhD

What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models? These were some of the questions discussed at the Payer Exchange Summit V.

October 25th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.

...

88 89 90 91 92 93 94 95 96

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions